AX-2026-042508

IGF-1 LR3 · 0.1 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2607-P5131

MARGINALIDENTITY CONSISTENT

Report ID: AX-2026-042508
Compound: IGF-1 LR3
Compound class: Growth-hormone axis peptides
Supplier: Homopeptide — Hunan Aslsen Technology Co., Ltd.
Batch / lot: HOMO-2607-P5131
Declared label claim: 0.10mg
Laboratory: Janoshik Analytical
Assay date: 18 Aug 2026
Submitted: 05 Sep 2026
Quarter: 2026-Q3
Submitter: b.espinoza
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.89	% area	≥ 95.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.11	% area	≤ 5.0	PASS
Largest single impurity	RP-HPLC — disulfide-scrambled isomer	0.48	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	9105.2412	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	9105.2703	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+3.2	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	6.22	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	3.99	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.57	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.09	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	15.79	min	16.92 ± 0.50 (normalised)	FAIL
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.15	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	57,262	—	≥ 20,000	PASS
Resolution to nearest impurity	vs disulfide-scrambled isomer	2.29	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 57,262, and skew follows the reported asymmetry factor of 1.15. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.48 % impurity against a 98.89 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	IGF-1 LR3 — main peak	15.79	4,806,361	98.89	—
2	disulfide-scrambled isomer	16.41	23,329	0.48	0.000
3	oxidised Met59 (+16 Da)	15.07	17,497	0.36	+15.995
4	des-13-residue N-extension (native IGF-1)	13.55	8,263	0.17	-1441.712
5	truncated (1-70)	13.85	2,916	0.06	-1385.688
6	aggregated dimer	18.99	1,944	0.04	+9105.241
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 9105.2412 Da, computed from C400H625N111O116S9. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 9105.2703 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
11+	828.7565	828.7591	0.0026	7.6
10+	911.5314	911.5343	0.0029	53.1
9+	1012.7007	1012.7040	0.0033	100.0
8+	1139.1624	1139.1661	0.0037	57.1
7+	1301.7560	1301.7602	0.0042	8.5

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.97	98.89	divergence +0.04 pp vs batch median
Total impurities (% area)	not stated	1.11
Largest single impurity (% area)	not stated	0.48
Water (%)	6.0	6.22
Counter-ion (%)	not stated	3.99
Peptide content (%w/w)	89.2	not determined
Endotoxin (EU/mg)	0.71	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 28 d) → laboratory (courier, cold pack, 5 d) → assay.
Assay date: 18 Aug 2026
Submitted to the index: 05 Sep 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That the protein is correctly folded. Reverse-phase chromatography measures hydrophobic heterogeneity. A correctly-massed, chromatographically-homogeneous recombinant protein can be entirely mis-paired at its disulfides. Purity here is an upper bound and nothing more.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

sole_source05 Sep 2026

On compounds with a single supplier, independently purchased records are the only thing preventing the evidence base from being entirely supplier-generated. They matter disproportionately there.

gradient_2505 Sep 2026

Normalisation assumes the gradient was linear and ran to completion. A method with an isocratic hold at the start breaks the assumption and the certificate will not mention the hold.

Section 7

Related records

Same batch — lot HOMO-2607-P5131 n=14

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042497	HOMO-2607-P5131	Janoshik	2026-Q3	98.89	6.25	—	Buyer-sourced	0	PASS
AX-2026-042498	HOMO-2607-P5131	PeptideMeter	2026-Q3	99.09	5.99	105.0	Buyer-sourced	0	PASS
AX-2026-042499	HOMO-2607-P5131	Medutest	2026-Q3	98.48	5.98	88.0	Buyer-sourced	1	MARGINAL
AX-2026-042500	HOMO-2607-P5131	Janoshik	2026-Q3	98.97	6.17	86.0	Supplier-supplied	1	MARGINAL
AX-2026-042501	HOMO-2607-P5131	Janoshik	2026-Q3	98.89	7.00	—	Buyer-sourced	0	PASS
AX-2026-042502	HOMO-2607-P5131	Kestrel	2026-Q3	99.36	6.39	96.0	Buyer-sourced	0	PASS
AX-2026-042503	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	0	PASS
AX-2026-042504	HOMO-2607-P5131	Janoshik	2026-Q3	99.08	6.26	105.0	Buyer-sourced	0	PASS
AX-2026-042505	HOMO-2607-P5131	PeptideMeter	2026-Q3	98.73	6.03	—	Buyer-sourced	0	PASS
AX-2026-042506	HOMO-2607-P5131	PeptideMeter	2026-Q3	98.58	6.21	—	Buyer-sourced	0	PASS
AX-2026-042507	HOMO-2607-P5131	Medutest	2026-Q3	99.26	6.28	88.0	Buyer-sourced	1	MARGINAL
AX-2026-042509	HOMO-2607-P5131	Medutest	2026-Q3	98.63	6.23	103.0	Buyer-sourced	0	PASS
AX-2026-042510	HOMO-2607-P5131	Janoshik	2026-Q3	99.00	6.36	95.0	Buyer-sourced	0	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent IGF-1 LR3 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042503	Homopeptide	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	0	PASS
AX-2026-042509	Homopeptide	HOMO-2607-P5131	Medutest	2026-Q3	98.63	6.23	103.0	Buyer-sourced	0	PASS
AX-2026-041930	SinoPep	SNP-2606-D4620	Medutest	2026-Q3	98.54	5.37	93.8	Buyer-sourced	0	PASS
AX-2026-041931	SinoPep	SNP-2606-D4620	PeptideMeter	2026-Q3	97.93	5.19	93.4	Buyer-sourced	0	PASS
AX-2026-041924	SinoPep	SNP-2606-D4620	Janoshik	2026-Q3	97.95	5.34	—	Buyer-sourced	0	PASS
AX-2026-042504	Homopeptide	HOMO-2607-P5131	Janoshik	2026-Q3	99.08	6.26	105.0	Buyer-sourced	0	PASS
AX-2026-042499	Homopeptide	HOMO-2607-P5131	Medutest	2026-Q3	98.48	5.98	88.0	Buyer-sourced	1	MARGINAL
AX-2026-041926	SinoPep	SNP-2606-D4620	VendorInvestigate	2026-Q3	98.74	5.45	98.9	Buyer-sourced	0	PASS

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Retatrutide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-042424	Semaglutide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	PASS
AX-2026-042503	IGF-1 LR3	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	PASS
AX-2026-042492	SS-31 (Elamipretide)	HOMO-2604-D5484	Medutest	2026-Q3	99.93	2.40	—	Buyer-sourced	PASS
AX-2026-042491	SS-31 (Elamipretide)	HOMO-2604-D5484	Kestrel	2026-Q3	99.93	3.24	—	Supplier-supplied	PASS
AX-2026-042473	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	PASS
AX-2026-042441	Retatrutide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-042474	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	PASS